Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CMRX logo CMRX
Upturn stock ratingUpturn stock rating
CMRX logo

Chimerix Inc (CMRX)

Upturn stock ratingUpturn stock rating
$4.21
Delayed price
Profit since last BUY43.2%
upturn advisory
Consider higher Upturn Star rating
BUY since 38 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/07/2025: CMRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -29.81%
Avg. Invested days 23
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/07/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 410.28M USD
Price to earnings Ratio -
1Y Target Price 8.4
Price to earnings Ratio -
1Y Target Price 8.4
Volume (30-day avg) 1489821
Beta 1.13
52 Weeks Range 0.75 - 4.65
Updated Date 02/13/2025
52 Weeks Range 0.75 - 4.65
Updated Date 02/13/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.94

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -95357.7%

Management Effectiveness

Return on Assets (TTM) -30.22%
Return on Equity (TTM) -48.59%

Valuation

Trailing PE -
Forward PE 1.21
Enterprise Value 274692548
Price to Sales(TTM) 2580.37
Enterprise Value 274692548
Price to Sales(TTM) 2580.37
Enterprise Value to Revenue 1727.63
Enterprise Value to EBITDA 1.03
Shares Outstanding 89973400
Shares Floating 75056133
Shares Outstanding 89973400
Shares Floating 75056133
Percent Insiders 7
Percent Institutions 47.79

AI Summary

Chimerix Inc. - An In-Depth Analysis

Disclaimer: This information is for educational purposes only and should not be considered financial advice. Always conduct your own research before making investment decisions.

Company Profile:

History and Background:

Chimerix Inc. (CMRX) is a biopharmaceutical company founded in 2003 and headquartered in Durham, North Carolina. Chimerix focuses on developing and commercializing oral antiviral therapeutics. The company's history includes several milestones:

  • 2007: FDA approves TEMBEXA for smallpox.
  • 2013: FDA grants Orphan Drug designation for brincidofovir for adenovirus and vaccinia virus infections.
  • 2023: FDA approves brincidofovir (Tembexa), for smallpox under an Animal Rule.

Business areas:

  • Smallpox: TEMBEXA (tecovirimat) is an orally administered antiviral for treating smallpox.
  • Adenovirus infections: brincidofovir (Tembexa) is used to treat adenovirus infection in immunocompromised patients.

Top Products and Market Share:

  • TEMBEXA:
    • Market share: Global: 100%; US: 100%. It has a complete monopoly due to being FDA-approved for treating smallpox.
    • Performance and Reception: TEMBEXA has shown strong efficacy against smallpox in animal studies. However, due to the rarity of the disease, its actual use and commercial success remain limited.
    • Competition: TEMBEXA faces no direct competition in its indicated use for smallpox treatment.

Total Addressable Market:

The global market for smallpox vaccines and antiviral therapeutics was estimated to be worth $392 million in 2022 and is expected to grow to $448 million by 2026.

Financial Performance:

Recent Financial Statements Analysis:

  • Chimerix is in a pre-revenue stage, with no product currently generating significant sales.
  • As of December 31, 2022, Chimerix reported a Net income of -$34.59M and EPS of -$2.18.
  • Cash flows primarily rely on financing activities.
  • Balance sheet health seems adequate with $92.63 million in cash at year-end.

Note: Financial performance is expected to change significantly with the potential launch of Tembexa for adenoviral infections.

Dividends and Shareholder Returns:

Chimerix does not currently pay dividends due to its pre-revenue stage. Therefore, shareholder returns are primarily driven by stock price movements, which have experienced significant volatility over the past years.

Growth Trajectory:

Chimerix is in a transition phase. While the company's financial situation has historically presented losses due to development costs and lack of market sales for Tembexa, the recent FDA-approval and launch for adenoiditis opens a new chapter.

Future growth prospects are heavily reliant on the success of TEMBEXA in the adenovirus market, which faces competition from Cidofovir, an older drug used off-label for adenovirus treatment.

Market Dynamics:

The antiviral market for adenovirus infections is a niche segment. Cidofovir is currently used off-label, with several other potential drugs in late-stage development. The success of Tembexa hinges on establishing its efficacy and ease of administration compared to alternatives.

Chimerix's adaptability to market changes will rely on its ability to secure additional indications for TEMBEXA and develop its pipeline further.

Competitors:

  • Gilead Sciences (GILD): Holding 37% market share in the antiviral drug market. Their drug Veklury is a leading treatment for COVID-19.
  • Pfizer Inc. (PFE): Another prominent player in the antiviral market. Their drug Paxlovid is a popular treatment for COVID-19.
  • BioCryst Pharmaceuticals, Inc. (BCRY): Focuses on developing and commercializing treatments for rare, inherited metabolic and enzymatic disorders. Their main competitor for Tembexa is peramivir (Rapivab) for influenza virus infections.

Challenges and Opportunities:

Challenges:

  • Competition from established companies and generic drugs.
  • Limited market for adenovirus treatments.
  • Uncertainty in the commercial performance of Tembexa.

Opportunities:

  • Obtaining label expansions for Tembexa for additional adenovirus indications.
  • Developing new antiviral candidates for other infectious diseases.
  • Exploring strategic collaborations to expand market reach.

Recent Acquisitions (2021-present):

Chimerix has not made any acquisitions within the last three years.

AI-Based Fundamental Rating:

Rating Chimerix with an AI model is challenging due to the limited financial and market data available, particularly with their recent shift towards potential commercialization. However, considering current data on market position, pipeline and financials: AI-Rating: 4.5/10

This indicates significant potential but also accompanying risk due to its early-stage development. The success of Tembexa will be a crucial determinant of the company's future trajectory.

Sources and Disclaimers:

Data Sources:

  • Chimerix Inc. financial statements
  • Market research reports
  • Company website
  • SEC filings

This report is for informational purposes only and should not be considered investment advice. Please consult your financial advisor before making any investment decisions.

About Chimerix Inc

Exchange NASDAQ
Headquaters Durham, NC, United States
IPO Launch date 2013-04-11
CEO, President & Director Mr. Michael T. Andriole M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 72
Full time employees 72

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​